Latest Headlines
-
Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service For Researchers And Healthcare Providers
2/13/2024
Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.
-
SinguLab® Announces Integration With PointClickCare
2/13/2024
SinguLab®, a nationwide provider of precision medicine and diagnostics solutions, today announced its expanded integration with PointClickCare Technologies Inc., the leading cloud-based software platform for the senior care continuum, enabling providers to quickly and easily identify potentially dangerous drug-gene interactions for their residents.
-
Paige Expands Its AppLab Marketplace With Six New Digital Pathology Providers To Deliver A More Robust And Streamlined User Experience For Diagnosing Cancer
2/8/2024
Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, today announced a significant expansion of its AppLab marketplace, with the addition of six new digital pathology and AI providers.
-
Volta Labs Partners With OEM By QIAGEN To Unlock Potential Of NGS Sample Prep
2/8/2024
Volta Labs, a genomics applications company, and the OEM business of QIAGEN, the leading global provider of Sample to Insight solutions, announced they will leverage their technologies to increase the availability of sample preparation kits for next-generation sequencing (NGS).
-
Lucid Diagnostics Executes Contract To Provide EsoGuard® Esophageal Precancer Testing As A Covered Benefit For 9/11 Responders And Survivors
2/8/2024
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that it has contracted with the World Trade Center Health Program ("WTCHP") to provide the EsoGuard® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program.
-
New Blood Bank Technology Prepares Students For Modern Laboratory Work
2/8/2024
ECU’s clinical laboratory science students — who after graduation run the nation’s medical labs in hospitals, for public health offices and in the pharmaceutical and biotech industry — got a huge boost recently with the acquisition of a new device that automates the process for identifying blood types.
-
Celerion Achieves Milestone With CLIA Certification For Its Bioanalytical Laboratory, Expanding Capabilities In Clinical Trials And Diagnostic Testing
2/6/2024
Celerion, a leading clinical research organization, proudly announces its recent achievement of obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification for its state-of-the-art bioanalytical laboratory located in Lincoln, Nebraska.
-
The FDA’s Proposed Ruling On Lab Tests Could Have Unintended Consequences
2/6/2024
Yale experts are raising concerns about a rule proposed by the U.S. Food and Drug Administration (FDA) to enforce the agency’s regulatory control over laboratory-developed tests, or LDTs. The tests play a critical role in filling gaps in commercial testing, such as diagnostic tests for rare diseases deemed unprofitable by manufacturers.
-
Volta Labs And Integrated DNA Technologies Partner To Advance Target Enrichment Workflows
2/6/2024
Volta Labs, a genomics applications company, and Integrated DNA Technologies (IDT), a leading provider of differentiated next generation sequencing (NGS) solutions, announced a partnership to further the shared mission of making NGS solutions more accessible.
-
Microbix Unveils Test Control For Gastric Ulcer Disease Pathogen
2/6/2024
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of a Quality Assessment Product (“QAP™”) for supporting the clinical use and accuracy of molecular (“MDx”) tests for infection with Helicobacter pylori (“H. pylori”), the bacterial cause of stomach ulcers, at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 8 to 10, 2024.